More than Just a Meeting
This year’s meeting is shaped by expert industry leaders tackling the same challenges you face every day and coming ready to share the strategies driving real progress.
Join the teams behind the breakthroughs and gain the insights you need to accelerate radioligand therapies from discovery through to commercialisation. Bring your team and leave equipped to confidently navigate every stage of TRP development.
How Can You Forge Long-Lasting, Hyper-Relevant TRP Connections? Here’s how:
Structured networking sessions.
➡️ Including speed networking, roundtables, pre-booked meetings, and poster sessions, are designed to facilitate targeted introductions, ensuring you meet every radiopharma expert in the room.
End-to-end Discussions
➡️From phase zero trials through to commercialization, take part in intimate sessions where discussions go beyond presentations, with direct Q&A with speakers, regulators, and peers throughouts
Pre-book 1‑2‑1 meetings with industry experts *NEW
➡️For the first time, schedule one‑to‑one meetings via the event app to move beyond business card exchanges and connect directly with targeted companies, speakers, and peers across discovery, preclinical, translational & clinical, and CMC & supply.
Four dedicated tracks
➡️Aligned to real radiopharma teams, discovery, preclinical, clinical, and CMC/supply chain, so every function can access highly relevant content and peer groups, enabling true cross-functional learning.
Informal networking
➡️Across breakfasts, coffee breaks, lunches, and evening receptions, creating the kind of environment where conversations naturally continue throughout the TRP Summit.
Explore the Full Event Guide
- 260+ Attendees from World-Leading RLT Companies
- 66+ Speakers including Novartis, AstraZeneca, RayzeBio & Convergent Therapeutics
- 8+ Hours of Dedicated Networking alongside pioneers in the RLT industry
- 4 Tracks of Content: An agenda built for your team, spanning from Discovery to
CMC & Supply Chain - 22+ C-Suite Speakers with direct influence on their companies’ pipelines & decision-making
